Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A ExpertiseNORFOLK, Va.--(BUSINESS WIRE)--ReAlta ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

OpenAI just released a report about healthcare drawn from anonymized chatbot conversations. The title could double as one of ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Plants mobilize their immune defenses far earlier than scientists have believed for decades—and through a previously ...

This population-based study shows that shared and pattern-specific blood biomarkers reflect biological vulnerability ...

A research team provides an overview of how engineered probiotics—genetically modified beneficial microbes—are being transformed into living medicines capable of sensing disease, delivering therapies, ...

The Asian Development Bank, with support from the Government of Austria and research partners including Emory University, piloted wastewater-based epidemiology in Nepal and the Philippines to show how ...

Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...